Tc-99m diethylenetriamine pentaacetic acid (DTPA): Is it reliable for assessment of methotrexate-induced cumulative effect on renal filtration in rheumatoid arthritis patients?  by Amin, Amr et al.
The Egyptian Rheumatologist (2013) 35, 5–8Egyptian Society for Joint Diseases and Arthritis
The Egyptian Rheumatologist
www.rheumatology.eg.net
www.sciencedirect.comORIGINAL ARTICLETc-99m diethylenetriamine pentaacetic acid (DTPA): Is it
reliable for assessment of methotrexate-induced cumulative
eﬀect on renal ﬁltration in rheumatoid arthritis patients?Amr Amin a,*, Dina Eﬀat b, Nabila Goher b, Basma Ramadan ba Nuclear Medicine Department, Faculty of Medicine, Cairo University, Egypt
b Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, EgyptReceived 24 September 2012; accepted 8 October 2012
Available online 1 December 2012*
M
45
E-
Pe
an
11
htKEYWORDS
Rheumatoid arthritis;
Methotrexate;
Methotrexate induced renal
toxicity;
GFR;
Gate’s methodCorresponding author. Ad
ohandeseen, Giza, Egypt. Te
.
mail address: amramin67@g
er review under responsibility
d Arthritis.
Production an
10-1164  2012 Egyptian So
tp://dx.doi.org/10.1016/j.ejr.2dress: 3
l.: +20 0
mail.com
of Egyp
d hostin
ciety for
012.10.00Abstract Methotrexate [MTX] is commonly employed as the initial DMARD used for treatment
of Rheumatoid arthritis [RA]. We aimed to contribute to the safety proﬁle of MTX by assessing its
cumulative effect on renal ﬁltration. Fifty two RA adult females with normal base-line serum cre-
atinine and GFR at the initial diagnosis of the disease were included. Group-1 [G1] included 30
patients [mean age 40.4 ± 4.4 years] on MTX and NSAIDS, while 22 RA patients [mean age
38.5 ± 8.2 years] who received NSAIDs only served as the control group [G2]. Renal function
was assessed by GFR-measurement using Technetium diethylenetriamine-pentaacetic acid [Tc-
99 m-DTPA] at the point of the study time corresponding to disease duration. 21/30 [70%] in
G1 showed reduced GFR compared to 6/22 [27.3%] in G2 [P0.007] with 3.3 ± 0.5% annual reduc-
tion of GFR. Reduced GFR in G1 showed signiﬁcant negative correlation with age [r= 0.396,
P= 0.005], MTX-cumulative dose [r= 0.263, P= 0.049], MTX-intake duration [r= 0.293,
P= 0.031] and NSAID-intake duration [r= 0.344, P= 0.014]. Low dose MTX has a slow
cumulative effect on renal ﬁltration manifested by GFR reduction over time that could be moni-
tored by Tc-99 m DTPA.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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11. Introduction
Rheumatoid arthritis (RA) is an autoimmune inﬂammatory
disorder with a prevalence of about 0.5–1% of the world pop-
ulation [1]. A variety of renal disorders can occur in RA pa-
tients due to the underlying disease, drugs used in treatment,
or concurrent renal disease [2].
Methotrexate (MTX) is commonly employed as the initial
disease modifying anti-rheumatic drug (DMARD) for treat-
ment of RA either as monotherapy or as ‘‘anchor drug’’ inuction and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
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tor agents [3]. Signiﬁcant nephrotoxicity due to MTX may oc-
cur with high doses, while with low doses there is a modest
decline in glomerular ﬁltration rate (GFR) [4]. MTX is primar-
ily cleared via the kidneys, with 80–90% excreted unchanged in
urine; hence impairment in GFR will result in its sustained ser-
um level that may induce bone marrow suppression or other
toxicities [4].
Rau and Herborn [5] reported that GFR was reduced by
10% during MTX treatment in RA patients without
co-medication. Seideman et al. concluded; low dose MTX
can impair GFR and that should be considered especially if
combined with other nephrotoxic drugs [6].
The cornerstone for diagnosing renal disease is GFR
estimation which is inﬂuenced by various factors including
structural and/or functional kidney disease, patient’s age,
weight, and body surface area. The gold standard for GFR
estimation is inulin-clearance, which is too costly and time-
consuming. In routine clinical practice, Chromium-51-ethyl-
enediaminetetraacetic acid (51Cr-EDTA) clearance is a widely
accepted and accurate substitute yet a very expensive screening
tool [7]. So, both remain essentially research tools and are not
used in clinical practice [8]. Thus, other isotope clearance
methods were validated, employing labeled diethylenetria-
mine-pentaacetic acid (DTPA) [9]. The value of GFR estima-
tion is strengthened by the fact that normal serum creatinine
may not be elevated until GFR is less than 50% of normal [10].
Till now, our knowledge of the toxicity proﬁle of MTX is
still being reﬁned, as either new toxic effects or modiﬁcations
in the behavior of some of the already known toxicities con-
tinue to come to light even after ﬁve decades of its use [11].
We aimed to evaluate the cumulative effect of MTX on
GFR in RA patients with normal serum creatinine using
Tc-99 m DTPA and correlate with various parameters to help
boost the overall safety of MTX on renal function.2. Materials and methods
The study was approved by the local ethics committee of
Cairo-University scientiﬁc review board and informed consent
was obtained from all subjects according to the Declaration of
Helsinki; General Assembly, October 2008. It included 52
adult female RA patients fulﬁlling 1987 revised ACR criteria
for the classiﬁcation of RA [12] and divided into two groups.
Group 1 [G1] included 30 patients [mean age 40.4 ± 4.4 years]
who received MTX [15–25 mg/week] with an intake duration
that ranged from 2 to 6 years [4.5 ± 0.5 years] and NSAIDs
[Diclofenac Sodium and Piroxicam]. Group 2 [G2] included
the other 22 RA patients who were age [mean age
38.5 ± 8.2 years], DAS28 and body mass index [BMI] matched
with G1 serving as control group, they received only similar
NSAIDs; with comparable disease duration. All had normal
serum creatinine and GFR using the Modiﬁcation of Diet in
Renal Disease Study Group [MDRD] formula [13] at the ini-
tial diagnosis of the disease. We excluded any patient with
abnormalities in blood glucose, lipid proﬁle, uric acid, urine
analysis [including microalbuminuria assay] and renal sonog-
raphy, uncontrolled hypertension, cardiac or hepatic insufﬁ-
ciency, cigarette smoking, BMI-based obesity, present or
past history of nephrotoxic drugs, and other autoimmune
diseases.The cumulative dose of MTX was estimated by multiplying
the current weekly dose by number of weeks since it was initi-
ated. BMI was calculated for all subjects and DAS28 score was
used to assess disease activity [14]. Renal function was assessed
by GFR-measurement using Tc-99 m-DTPA; Gates’ method
[15] at the point of the study time corresponding to disease
duration.
Patients’ categorization was performed according to the
recommendations of Kidney–Dialysis Outcomes and Quality
Initiative Stages [K/DOQI] into normal and chronic kidney
disease (CKD) using generated GFR values [16]. The % an-
nual GFR reduction was calculated by the following formula:
% Annual GFR reduction ¼ \Base-Line GFRGFR at
the study time"=Disease duration in years  100
Statistics: Data were analyzed by SPSS version 14. Contin-
uous data were presented as means ± SD, while discrete data
were shown as numbers and percentages. Cross tabulation was
utilized to describe the relations between variables using the
contingency coefﬁcient. Levene’s test (F-test) for the equality
of variances was used and t-test for testing differences between
parametric data. Correlation between parametric variables was
performed using Pearson’s correlation coefﬁcient. Z propor-
tion was used to test the statistical difference between both
groups regarding GFR. Signiﬁcance was deﬁned as P< 0.05
throughout.3. Results
In G1 and G2, the means of disease duration were 6 ± 0.5 and
6 ± 0.4 years, DAS28 3.3 ± 0.8 and 3.8 ± 0.5 and BMI val-
ues (23.93 ± 2.62) and (22.85 ± 3.61), respectively. Patients’
laboratory ﬁndings are shown in Table 1. MTX and NSAID
regimens of G1 are detailed in Table 2. In G2, the mean of
NSAID duration intake was 5.6 ± 0.8 being almost identical
to that in G1 and the same implies to dosage and intake
regimens.
Base-line GFR was normal in G1 [Range 95–125;
100 ± 9.5 ml/min] and G2 [Range 94–128; 99 ± 11.5 ml/
min]. At the study time in G1; GFR ranged 57–120
[75.6 ± 12.7 ml/min] being reduced in 21 (70%) patients while
in G2; GFR ranged 59–115 [98.8 ± 7.1 ml/min] being reduced
in 6 (27.3%) patients [Table 3] with a signiﬁcant difference be-
tween both groups regarding patients’ number with reduced
GFR [P0.007] and their GFR means [P0.003]. Annual reduc-
tion of GFR was found to be 3.3 ± 0.5% throughout the dis-
ease duration of affected cases in G1. Correlations between
GFR in G1 and G2 with various disease parameters showed
signiﬁcant negative correlations with patients’ age (r-0.396,
P0.005), MTX cumulative dose (r-0.263, P0.049), duration of
MTX intake (r-0.293, P0.031) and duration of NSAID intake
(r-0.344, P0.014) in G1 while no signiﬁcant correlations were
provoked with disease duration and DAS28. In G2 no similar
signiﬁcant correlations were elicited regarding the same
parameters.4. Discussion
This study was carried out on 52 RA patients with normal
serum creatinine who were divided into G1 [on MTX and
Table 1 Laboratory data of G1 and G2 RA patients.
Laboratory data G1 (n= 30) G2 (n= 22)
Range Mean ± SD Range Mean ± SD
ESR (mm/1st hour) 15–110 44.5 ± 18.90 20–120 61.8 ± 7.3
Hemoglobin (gm/dl) 9–13 11.2 ± 0.97 9–14.5 12.7 ± 0.4
WBCs/mm3 4–11 6.81 ± 1.81 5–11 6.8 ± 0.55
Platelets ·103/mm3 160–450 321.98 ± 69.88 160–429 301.6 ± 19.49
Serum creatinine (mg/dl) 0.3–1 0.61 ± 0.16 0.3–0.9 0.6 ± 0.04
ALT (IU/L) 12–30 17 ± 5.38 9–30 16.7 ± 1.8
Microalbuminuria (mg/gm) 4–19 10 ± 5 5–17 11 ± 5
Urine analysis No abnormality No abnormality
RF positive (%) 63.3 61.8
G1: RA patients on MTX and NSAIDs; G2: RA patients on NSAIDs only.
Table 3 Distribution of RA patients according to GFR
results (K/DOQI 2002a).
Stages G1 (n= 30) G2 (n= 22)
Stage 0 9 (30%) 16 (72.7%)
Stage I 0 (0%) 0 (0%)
Stage II 20 (66.7%) 5 (22.7%)
Stage III 1 (3.3%) 1 (4.6%)
Stage V 0 (0%) 0 (0%)
Stage VI 0 (0%) 0 (0%)
G1: RA patients on MTX and NSAIDs; G2: RA patients on
NSAIDs only.
a (K/DOQI 2002): Kidney Disease Outcomes Quality Initiative.
Table 2 Medical treatment of G1 RA patients.
Range Mean ± SD
MTX
MTX dose/week (mg/w) 15–25 18.56 ± 3.09
Duration of MTX intake (years) 0.2–10 6 ± 0.5
MTX cumulative dose (mg) 3080–4550 3015 ± 630
NSAIDS
Duration of NSAID intake (years) 0.4–10 6 ± 0.4
Types [dose/day (mg/d)]
 Diclofenac sodium 50–100 72.6 ± 23
 Piroxicam 10–20 15 ± 4
Tc-99m diethylenetriamine pentaacetic acid (DTPA): 7NSAIDs] and G2 [only on NSAIDs]. G1 showed a high prev-
alence of reduced GFR at the study time [70%] compared to
G2 [27.3%] with 3.3 ± 0.5% annual reduction of GFR in
G1 that may suggest the slow cumulative negative effect of
MTX on GFR. To our knowledge, no previous studies have
reported GFR estimation using Tc-99 m DTPA in RA patients
to assess such effect of MTX.
In routine clinical practice, clinicians have relied on serum
creatinine to assess renal function. However, its level depends
also on muscle mass since creatinine is derived from muscle
creatine. It cannot therefore, in isolation, accurately reﬂect
kidney function of an individual as it varies according to fac-
tors such as age, sex, body mass and ethnic origin. Reduced
GFR can be present despite normal creatinine which may
not be elevated until GFR is less than 50% of normal [9,10].
Creatinine clearance can be a surrogate marker of GFR
since creatinine is freely ﬁltered by the glomerulus, but is alsoexcreted by the renal tubules in very small amounts so it over-
estimates GFR by 10–20%. Also, its reliability is directly
dependent on properly timed and precisely collected 24-h urine
sample which is a usual obstacle especially in females together
with 20% day to day variation in its value [9]. Modiﬁcation of
Diet in Renal Disease Study Group [MDRD] and Cockcroft
Gault formulas are widely used in clinical settings and are con-
sidered among the most accurate methods, however MDRD
was not speciﬁcally validated for RA patients [17] and both
were reported to be less accurate than radionuclide methods
[9,18].
A signiﬁcant statistical difference was found between G1
and G2 as regards patients with reduced GFR and their
GFR-means. Also, in G1 signiﬁcant negative correlations be-
tween GFR and MTX cumulative dose and intake duration
as well as NSAID were provoked. Seidman et al. [6] reported
that a low dose MTX treatment may signiﬁcantly impair kid-
ney function; however they used 51Cr-EDTA for GFR estima-
tion while we utilized Tc-99 m DTPA being comparable to the
former [19]. Also, Rau and Herborn [5] reported 10% reduc-
tion in GFR during MTX treatment in RA patients without
co-medication. Verstappen et al. [20] studied the toxicity of
low dose MTX and reported a trend toward an association be-
tween diminished creatinine clearance and MTX. It is sug-
gested that as MTX breaks down, there are pieces that are
not soluble in acidic urine that can precipitate and accumulate,
causing slow toxicity to the kidneys and renal dysfunction as
tubular precipitation of such insoluble crystals can increase in-
tra-tubular pressure; this opposes glomerular ﬁltration pres-
sure and can decrease GFR [21].
Townsend [22] mentioned that NSAIDs can impair GFR
while, Harirforoosh and Jamali [23] stated a relationship be-
tween their high plasma concentration and renal adverse ef-
fects, with more tendency in patients with diabetes, heart
failure, renal dysfunction and elderly. In our study, both
groups received NSAIDs which do not alter absorption, pro-
tein binding, distribution, half-life or elimination of MTX
[24]. Weinblatt [4] reported that an increase in free MTX be-
cause of displacement from albumin by NSAIDs can occur,
but this is generally of limited clinical signiﬁcance with low
dose MTX, because its increase is usually modest. Also,
Fitzgerald and Patrono [25] reported similar ﬁndings. Thus
based on the aforementioned data, MTX is the solely incrimi-
nated drug for the higher percentile of our RA patients with
reduced GFR in G1 [70%]. Daoussis et al. [26] used MDRD
8 A. Amin et al.in 400 RA patients for GFR estimation and found no signiﬁ-
cant correlation between GFR with DAS28 score or disease
duration and reported signiﬁcant negative correlation with pa-
tients’ age; these ﬁndings were all in agreement with ours.
In this study, MTX showed a negative cumulative effect on
GFR measured with Tc-99 m DTPA which is of recent critical
relevance as current data have emerged indicating a strong link
and cross talk between cardiovascular risk and renal dysfunc-
tion [27]. Thus awareness of such drawback; even modest must
be considered in the prevention strategies for cardiovascular
disease in RA patients.
In conclusion, we suggest that MTX has an adverse effect
on GFR, so its prescription rates should be based on a reliable
method for GFR estimation as Tc-99 m DTPA to deﬁne those
likely to beneﬁt from its dose adjustment and avoidance of
those drugs with predictable adverse effects on renal function
as NSAIDs.Acknowledgement
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